Pembrolizumab (Genetical Recombination) (100mg/4mL/1vial),and 16 other contracts

2026-11-03

Official in charge of disbursement of the procuring entity : Abiko Kosei, The Obligating Officer Trustee, Shinshu University Classification of the products to be procured : Nature and quantity of the products to be purchased : A Pembrolizumab (Genetical Recombination) (100mg/4mL/1vial) B Atezolizumab (Genetical Recombination) (1,200mg/20mL/1vial) C Canakinumab (Genetical Recombination) (150mg/1mL/1vial) D Durvalumab (Genetical Recombination) (500mg/10mL/1vial) E Nivolumab (Genetical Recombination) (240mg/24mL/1vial) F Aflibercept (Genetical Recombination) (2mg/0.05mL/1vial×1vial) G Ravulizumab (Genetical Recombination) (1,100mg/11mL/1vial) H Ravulizumab (Genetical Recombination) (300mg/3mL/1vial) Ⅰ Pabinafus Alfa (Genetical Recombination) (10mg/1vial) J Tafamidis (61mg/CP/PTP/14CP) K Vutrisiran Sodium (25mg/0.5mL/1syringes) L Pertuzumab (Genetical Recombination) (600mg)/ Trastuzumab (Genetical Recombination) (600mg)/Vorhyaluronidase Alfa (Genetical Recombination) (2,000mg) (10mL/1vial) M Teprotumumab (Genetical Recombination) (500mg/1vial) N tisagenlecleucel (INN) (1bag) O idecabtagene vicleuce (L INN) (1bag) P axicabtagene ciloleucel (INN) (1bag) Q lisocabtagene maraleuce (L INN) (1set) Set Delivery period : From April, 202 through 3 March, 202 Delivery place : Shinshu University Hospital Qualifications for participating in the tendering procedures : Suppliers eligible for participating in the proposed tender are those who shall : A not come under Article and of the Regulation concerning the Contract for Shinshu University, B have the Grade A, Grade B or Grade C qualification during fiscal 202 in the Kanto・Koshinetsu area in sale of product for participating in tenders by Single qualification for every ministry and agency, or in tenders by Shinshu University, C not be currently under a suspension of business order as instructed by The Obligating Officer. D prove to have obtained the first-class license for selling drugs in accordance with the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices Time limit of tender : 1 : 0 1 March, 202 Contact point for the notice : Nishizawa Kana, Procurement Section, Accounting Division, Shinshu University Hospital, 3-1- Asahi Matsumoto-shi Nagano 390-862 Japan, TEL 0263-37-274 ⑼ Please be noted that if it is indicated that environmental conditions relating to the procurement are laid down in its tender documents.

Japan

2026-03-26